Citations

Clear

117 citation(s) found for "Carson, C C".

The Obstetric Medicine Listserv: review of controversies surrounding thrombophilia testing
Jörn, H., Carson, Michael

Mayo Clinic

Obstetric Medicine | March 5, 2012 | Volume: 5 | Issue: 1 | Pages: 22-24

10.1258/om.2011.110083 | PMID 27579127 Get It

A woman with no significant personal or family history of thrombosis asked her internist to obtain a thrombophilia work-up prior to starting the combined oral contraceptive for dysmenorrhoea, after another physician advised her to have the test. The case was sent to an international email discussion group where the consensus was that testing should not be done. The responses of the group and review of this controversial topic are presented.
BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma
Kim, Kevin B. , Sosman, Jeffrey A. , Fruehauf, John P. , Linette, Gerald P. , Nguyen, Hoa , Cheverton, Peter, Chen, Daniel S. , Peterson, Amy , Carson, William E. , Markovic, Svetomir N. , McDermott, David F. , Weber, Jeffrey S. , Peterson, Amy , O'Day, Steven J , Carson, William E

Mayo Clinic

Journal of Clinical Oncology | November 29, 2011 | Volume: 30 | Issue: 1 | Pages: 34-41

10.1200/jco.2011.34.6270 | PMID 22124101 Get It

Purpose Metastatic melanoma, a highly vascularized tumor with strong expression of vascular endothelial growth factor, has an overall poor prognosis. We conducted a placebo-controlled, double-blind phase II study of carboplatin plus paclitaxel with or without bevacizumab in patients with previously untreated metastatic melanoma. Patients and Methods Patients were randomly assigned in a two-to-one ratio to carboplatin (area under the curve, 5) plus paclitaxel (175 mg/m 2 ) and bevacizumab (15 mg/kg; CPB) or placebo (CP) administered intravenously once every 3 weeks. Progression-free survival (PFS) was the primary end point. Secondary end points included overall survival (OS) and safety. Results Two hundred fourteen patients (73% with M1c disease) were randomly assigned. With a median follow-up of 13 months, median PFS was 4.2 months for the CP arm (n = 71) and 5.6 months for the CPB arm (n = 143; hazard ratio [HR], 0.78; P = .1414). Overall response rates were 16.4% and 25.5%, respectively (P = .1577). With 13-month follow-up, median OS was 8.6 months in the CP arm versus 12.3 months in the CPB arm (HR, 0.67; P = .0366), whereas in an evaluation 4 months later, it was 9.2 versus 12.3 months, respectively (HR, 0.79; P = .1916). In patients with elevated serum lactate dehydrogenase (n = 84), median PFS and OS were longer in the CPB arm (PFS: 4.4 v 2.7 months; HR, 0.62; OS: 8.5 v 7.5 months; HR, 0.52). No new safety signals were observed. Conclusion The study did not meet the primary objective of statistically significant improvement in PFS with the addition of bevacizumab to carboplatin plus paclitaxel. A larger phase III study will be necessary to determine whether there is benefit to the addition of bevacizumab to carboplatin plus paclitaxel in this disease setting.
Plasma Cell Cerebrospinal Fluid Pleocytosis Does Not Predict West Nile Virus Infection
Jordan, Michael, Nagpal, Avish , Newman, William P. , Thompson, Paul A. , Carson, Paul J.

Mayo Clinic

Journal of Biomedicine and Biotechnology | November 2, 2011 | Volume: 2012 | Issue: No issue available | Pages: 1-3

10.1155/2012/697418 | PMID 22131822 Get It

Purpose. Diagnosis of WNV (WNV) relies upon serologic testing which may take several days after the onset of clinical symptoms to turn positive. Anecdotal reports suggest the presence of plasma cells or plasmacytoid lymphocytes in the cerebrospinal fluid (CSF) may be an early indicator of WNV infection.Methods. The CSFs of 89 patients (12 with WNV, 12 with other viral illness{OVI}, and 65 with nonviral illness{NVI}) were compared for the presence of either plasma cells or plasmacytoid lymphocytes.Results. Plasma cells were rarely seen in any of the patients. Plasmacytoid lymphocytes were more commonly seen in WNV (58%) and OVI (50%) than NVI (11%). The differences were significant for WNV versus NVI, but not WNV versus OVI (P<0.001andP=0.58,resp.).Conclusions. A CSF pleocytosis with plasma cells or plasmacytoid lymphocytes was neither sensitive nor specific for the diagnosis of WNV infection.
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
Carson, Kenneth R. , Evens, Andrew M. , Richey, Elizabeth, Focosi, Daniele , Seymour, John F. , Laubach, Jacob P. , Bawn, Susie D., Gordon, Leo I. , Furman, Richard R. , Zelenetz, Andrew D. , Mamtani, Ronac , Raisch, Dennis W., Dorshimer, Gary W., Rosen, Steven T. , Muro, Kenji , Gottardi-Littell, Numa R., Talley, Robert L., Green, David , Major, Eugene O. , Bennett, Charles L. , Habermann, Thomas M. , Winter, Jane N. , Vose, Julie M. , Sartor, Oliver , Gordon, Leo I , Zelenetz, Andrew D , Evens, Andrew M , Focosi, Daniele

Mayo Clinic

Blood | March 6, 2009 | Volume: 113 | Issue: 20 | Pages: 4834-4840

10.1182/blood-2008-10-186999 | PMID 19264918 Get It

Rituximab improves outcomes for persons with lymphoproliferative disorders and is increasingly used to treat immune-mediated illnesses. Recent reports describe 2 patients with systemic lupus erythematosus and 1 with rheumatoid arthritis who developed progressive multifocal leukoencephalopathy (PML) after rituximab treatment. We reviewed PML case descriptions among patients treated with rituximab from the Food and Drug Administration, the manufacturer, physicians, and a literature review from 1997 to 2008. Overall, 52 patients with lymphoproliferative disorders, 2 patients with systemic lupus erythematosus, 1 patient with rheumatoid arthritis, 1 patient with an idiopathic autoimmune pancytopenia, and 1 patient with immune thrombocytopenia developed PML after treatment with rituximab and other agents. Other treatments included hematopoietic stem cell transplantation (7 patients), purine analogs (26 patients), or alkylating agents (39 patients). One patient with an autoimmune hemolytic anemia developed PML after treatment with corticosteroids and rituximab, and 1 patient with an autoimmune pancytopenia developed PML after treatment with corticosteroids, azathioprine, and rituximab. Median time from last rituximab dose to PML diagnosis was 5.5 months. Median time to death after PML diagnosis was 2.0 months. The case-fatality rate was 90%. Awareness is needed of the potential for PML among rituximab-treated persons.
PIK3CA Gene Mutations in Pediatric and Adult Glioblastoma Multiforme
Gallia, Gary L. , Rand, Vikki , Siu, I‐Mei, James, C. David , Marie, Suely Kazue Nagahashi , Oba‐Shinjo, Sueli Mieko , Carlotti, Carlos Gilberto , Caballero, Otávia L., Simpson, Andrew J.G., Brock, Malcolm V., Massion, Pierre P. , Carson, Benjamin S., Riggins, Gregory J. , Eberhart, Charles G.

Mayo Clinic

Molecular Cancer Research | October 18, 2006 | Volume: 4 | Issue: 10 | Pages: 709-714

10.1158/1541-7786.mcr-06-0172 | PMID 17050665 Get It

Abstract The phosphatidylinositol 3-kinases (PI3K) are a family of enzymes that relay important cellular growth control signals. Recently, a large-scale mutational analysis of eight PI3K and eight PI3K-like genes revealed somatic mutations in PIK3CA, which encodes the p110α catalytic subunit of class IA PI3K, in several types of cancer, including glioblastoma multiforme. In that report, 4 of 15 (27%) glioblastomas contained potentially oncogenic PIK3CA mutations. Subsequent studies, however, showed a significantly lower mutation rate ranging from 0% to 7%. Given this disparity and to address the relation of patient age to mutation frequency, we examined 10 exons of PIK3CA in 73 glioblastoma samples by PCR amplification followed by direct DNA sequencing. Overall, PIK3CA mutations were found in 11 (15%) samples, including several novel mutations. PIK3CA mutations were distributed in all sample types, with 18%, 9%, and 13% of primary tumors, xenografts, and cell lines containing mutations, respectively. Of the primary tumors, PIK3CA mutations were identified in 21% and 17% of pediatric and adult samples, respectively. No evidence of PIK3CA gene amplification was detected by quantitative real-time PCR in any of the samples. This study confirms that PIK3CA mutations occur in a significant number of human glioblastomas, further indicating that therapeutic targeting of this pathway in glioblastomas is of value. Moreover, this is the first study showing PIK3CA mutations in pediatric glioblastomas, thus providing a molecular target in this important pediatric malignancy. (Mol Cancer Res 2006;4(10):709–14)